In 2022, the development of traditional Chinese medicine industry will face great challenges!

Since the beginning of this year, the reform and rectification actions for traditional Chinese medicine have received more and more attention from the policy level
.
On January 24, the State Food and Drug Administration deployed in-depth special rectification actions for drug safety at the 2022 National Drug Supervision and Administration and Party Style and Clean Government Construction Work Conference
.
On February 11, the State Food and Drug Administration re-deployed, re-emphasized and implemented the in-depth drug safety special rectification action
.
At the end of March, the notice of the "14th Five-Year Plan for the Development of Traditional Chinese Medicine" also proposed to build a high-level traditional Chinese medicine inheritance protection and scientific and technological innovation system, and to reform and improve the traditional Chinese medicine registration management
.
The plan also stated that it is necessary to optimize the clinical evidence system of traditional Chinese medicine, establish a "three-in-one" Chinese medicine registration review evidence system of traditional Chinese medicine theory, human experience and clinical trials, and actively explore the establishment of a real-world research evidence system for traditional Chinese medicine
.
On April 24, in order to implement the deployment of the in-depth special rectification action for drug safety, the State Food and Drug Administration held a promotion meeting for the special rectification of traditional Chinese medicines
.
The meeting summarized the current achievements in the special rectification of traditional Chinese medicine and the supervision of the whole life cycle of traditional Chinese medicine, and redeployed, emphasized and implemented the key tasks
.
Among them, deepening the reform of Chinese medicine review and approval is a highlight
.
It is understood that, for a long time, how to build a new Chinese medicine evaluation mechanism, efficacy evaluation standards, and Chinese medicine quality and safety evaluation system that conform to the characteristics and development laws of traditional Chinese medicine has always been a constraint to the innovative research and development of traditional Chinese medicine
.
In this promotion meeting, it was clearly pointed out that the reform of the review and approval and supervision system and mechanism of traditional Chinese medicine will be deepened
.
Continue to improve the system construction of laws and regulations, technical specifications and guiding principles, optimize the traditional Chinese medicine registration management system, accelerate the construction of a review evidence system combining traditional Chinese medicine theory, human experience and clinical trials, and strictly regulate the approval, filing and dispensing of traditional Chinese medicine preparations in medical institutions , to promote the innovative research and development of new traditional Chinese medicines and the innovation and transformation of traditional Chinese medicine preparations in medical institutions, and comprehensively promote the inheritance, innovation and development of traditional Chinese medicines
.
In addition, it is worth mentioning that the promotion meeting also proposed that Chinese herbal decoction pieces should not be commissioned for production: the quality and safety supervision of Chinese herbal medicines should be strengthened.

.
Efforts shall be made to strengthen the quality supervision of TCM decoction pieces, and urge production enterprises to implement whole-process management of TCM decoction pieces, and shall not entrust production and other contents
.
On the whole, traditional Chinese medicine has received more extensive attention and recognition
.
From the national to the local, a series of policies are also continuously promoting the more standardized and high-quality development of traditional Chinese medicine
.
In this context, the industry expects that in 2022, the traditional Chinese medicine industry will face a major rectification
.
This will play an important role in boosting the development of China's traditional Chinese medicine industry and further enhance industrial efficiency
.
But at the same time, it should be noted that traditional Chinese medicine enterprises also need to strictly control all aspects, adjust production and operation strategies in a timely manner, improve product quality, and standardize development, so as to better respond to various random inspections and rectifications and gain long-term competitiveness
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.